Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Lew

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Trends in Pharmacological Sciences|April 6, 2006
Principles: when there should be no difference--how to fail to reject the null hypothesisMichael J Lew
British Journal of Pharmacology|March 8, 2012
Bad statistical practice in pharmacology (and other basic biomedical disciplines): you probably don't know PMichael J Lew
Handbook of Experimental Pharmacology|January 4, 2020
A Reckless Guide to P-values : Local Evidence, Global ErrorsMichael J Lew
ANZ Journal of Surgery|August 22, 2009
Estimating the risk of rare complications: is the 'rule of three' good enough?John Ludbrook, Michael J Lew
Biochemical Pharmacology|March 24, 2004
The two-state model of antagonist-AT1 receptor interaction: an hypothesis defended but not testedMichael J Lew, James Ziogas
Biochemical Pharmacology|February 23, 2016
Biased signalling from the glucocorticoid receptor: Renewed opportunity for tailoring glucocorticoid activityChristine R Keenan, Michael J Lew, Alastair G Stewart
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 24, 2017
Cortisol limits selected actions of synthetic glucocorticoids in the airway epitheliumDanica Prodanovic, Christine R Keenan, Shenna Langenbach, et al.
The Journal of Biological Chemistry|August 30, 2008
A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligandCeline Valant, Karen J Gregory, Nathan E Hall, et al.
Molecular Pharmacology|July 22, 2010
Ligand-supported purification of the urotensin-II receptorAnn T Du, Döne Onan, Diem T Dinh, et al.
Molecular Pharmacology|March 20, 2002
Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptorsAlice C Holloway, Hongwei Qian, Luisa Pipolo, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Trends in Pharmacological Sciences|April 6, 2006
Principles: when there should be no difference--how to fail to reject the null hypothesisMichael J Lew
British Journal of Pharmacology|March 8, 2012
Bad statistical practice in pharmacology (and other basic biomedical disciplines): you probably don't know PMichael J Lew
Handbook of Experimental Pharmacology|January 4, 2020
A Reckless Guide to P-values : Local Evidence, Global ErrorsMichael J Lew
ANZ Journal of Surgery|August 22, 2009
Estimating the risk of rare complications: is the 'rule of three' good enough?John Ludbrook, Michael J Lew
Biochemical Pharmacology|March 24, 2004
The two-state model of antagonist-AT1 receptor interaction: an hypothesis defended but not testedMichael J Lew, James Ziogas
Biochemical Pharmacology|February 23, 2016
Biased signalling from the glucocorticoid receptor: Renewed opportunity for tailoring glucocorticoid activityChristine R Keenan, Michael J Lew, Alastair G Stewart
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 24, 2017
Cortisol limits selected actions of synthetic glucocorticoids in the airway epitheliumDanica Prodanovic, Christine R Keenan, Shenna Langenbach, et al.
The Journal of Biological Chemistry|August 30, 2008
A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligandCeline Valant, Karen J Gregory, Nathan E Hall, et al.
Molecular Pharmacology|July 22, 2010
Ligand-supported purification of the urotensin-II receptorAnn T Du, Döne Onan, Diem T Dinh, et al.
Molecular Pharmacology|March 20, 2002
Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptorsAlice C Holloway, Hongwei Qian, Luisa Pipolo, et al.
Pageof 2